At a glance: The DESTINY-Breast trials
- 24-03-2025
- Breast Cancer
- Clinical Trial Summary
- Article
The antibody–drug conjugate trastuzumab deruxtecan is being investigated in the DESTINY-Breast trials for the treatment of breast cancer.
The antibody–drug conjugate trastuzumab deruxtecan is being investigated in the DESTINY-Breast trials for the treatment of breast cancer.